Market research
CRVS Corvus Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 33.1429
- Dividend yield
- Not available
- Beta
- 0.87
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US2210151005
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 33.1429
- Dividend yield
- Not available
- Beta
- 0.87
About
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CRVS discussion.
5 years, 4 months ago
Corvus Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 27.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Corvus Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.9% to $-6K since the same quarter in the previous year.
Finally, its free cash flow grew by 2.7% to $-8M since the same quarter in the previous year.
Based on the above factors, Corvus Pharmaceuticals, Inc gets an overall score of 3/5.